Denali Therapeutics Inc. DNLI Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s share-based payment award options outstanding - number?
- Denali Therapeutics Inc. (DNLI) reported share-based payment award options outstanding - number of 22.5M in Q1 2026.
- How has Denali Therapeutics Inc.'s share-based payment award options outstanding - number changed year-over-year?
- Denali Therapeutics Inc.'s share-based payment award options outstanding - number increased by 1.6% year-over-year, from 22.2M to 22.5M.
- What is the long-term trend for Denali Therapeutics Inc.'s share-based payment award options outstanding - number?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s share-based payment award options outstanding - number has grown at a 10.5% compound annual growth rate (CAGR), from 13M to 21.3M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.